News & events
News & events
Find out about our latest news and events.
The discovery of a new critical enzyme could help engineer climate resilient crops capable of sucking far more carbon dioxide from the atmosphere in a much more efficient way.
Professor Alexander Maier wants us to change our mind about parasites.
Meet the PhD researcher exploring how bacterial proteins could hold the key to reducing our reliance on fossil fuels.
Researchers have discovered why malaria parasites are vulnerable to some drug therapies but resistant to others, offering scientists another piece of the puzzle in the global fight against the disease.
A low-cost, non-toxic cancer treatment has been developed by researchers at The Australian National University (ANU). The treatment uses dead bacteria to help kick-start the immune system and shrink cancer.
Researchers from The Australian National University (ANU) have exposed a fatal flaw in the deadly parasite that causes malaria - one of the world's biggest killers.
Bacterial infections remain a global public health challenge and there is a critical need for the identification and molecular understanding of new targets for antimicrobial design.
Current treatments for malaria are threatened by drug resistance, and new antimalarials are urgently required to ensure the continued ability to treat malaria infections into the future.
B0AT1 (Slc6a19) is a sodium-dependent neutral amino acid transporter catalyzing the secondary active transport of neutral amino acids across the brush border membrane of the kidney and intestine.
Malaria is an ancient disease leading to the death of more than half a million people every year.
Bacterial flagella self-assemble a strong, multi-component drive shaft that couples rotation in the inner membrane to the microns-long flagellar filament that powers bacterial swimming in viscous fluids.
The antimalarial drug amodiaquine has been around for nearly 60 years during which time it has been deployed as a monotherapy, then removed from recommendations due to toxicity fears, re-instated, and is now deployed in artemisinin-based combinations therapies to combat malaria.